To sum up, PYGL activates GSH metabolism to reduce ROS level, which suppresses the function of TP53, and ultimately promotes the evolvement and decrease the chemosensitivity of HNSCC. This evidence concerns the gene TP53 and head and neck squamous cell carcinoma.